000			03314nam a22005537a 4500
008			180619s20182018 xxu||||| |||| 00| 0 eng d
022			_a0021-972X
024			_a10.1210/jc.2017-02725 [doi]
024			_a4993640 [pii]
040			_aOvid MEDLINE(R)
099			_a29741712
245			_aEliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road?.
251			_aJournal of Clinical Endocrinology & Metabolism. 103(5):1813-1817, 2018 May 01.
252			_aJ Clin Endocrinol Metab. 103(5):1813-1817, 2018 May 01.
253			_aThe Journal of clinical endocrinology and metabolism
260			_c2018
260			_fFY2018
266			_d2018-06-19
501			_aAvailable online through MWHC library: 1999- June 2013, Available in print through MWHC library: 1999 - 2006
520			_aBackground: Unlike virtually all other cancer types, thyroid cancer is unique in that patient age is a key component in its staging. Pathologists and clinicians worldwide have accepted an age cutoff of 45 years for staging; in 2018, this advances to age 55 years in the eighth edition of the American Joint Commission on Cancer staging system.
520			_aConclusions: Among all cancers, age has an important role in only thyroid cancer staging. The consideration of age as a continuous variable and the search for age-associated prognostic variables could elucidate a more accurate staging system.
520			_aEvidence Acquisition: Clinical and basic research studies, reviews, and previous editions of consensus statements regarding thyroid cancer staging were reviewed, with particular focus on the influence of age in thyroid cancer prognosis.
520			_aEvidence Synthesis: The majority of findings report an association of age with thyroid cancer survival but do not support a specific age cutoff; rather, they suggest that outcome is affected by age as a continuous variable. Conceivably, other factors interact with age on a continuous basis over time, affecting prognosis. When identified, these factors could alter our current concept of the importance of an age cutoff in staging.
520			_aPurpose: This perspective briefly reviews the basis for this practice and challenges it as no more appropriate than for other malignancies.
546			_aEnglish
650			_a*Adenocarcinoma, Follicular/pa [Pathology]
650			_a*Aging/ph [Physiology]
650			_a*Carcinoma, Papillary/pa [Pathology]
650			_a*Neoplasm Staging/st [Standards]
650			_a*Thyroid Neoplasms/pa [Pathology]
650			_aAge Factors
650			_aDiagnostic Techniques, Endocrine/st [Standards]
650			_aHumans
650			_aNeoplasm Staging/mt [Methods]
650			_aPrognosis
650			_aReference Values
651			_aMedStar Health Research Institute
651			_aMedStar Washington Hospital Center
656			_aMedicine/Endocrinology
656			_aMedicine/Nuclear Medicine
657			_aJournal Article
700			_aBurman, Kenneth D
700			_aVan Nostrand, Douglas
700			_aWartofsky, Leonard
700			_aYlli, Dorina
790			_aBurman KD, Van Nostrand D, Wartofsky L, Ylli D
856			_uhttps://dx.doi.org/10.1210/jc.2017-02725 _zhttps://dx.doi.org/10.1210/jc.2017-02725
942			_cART _dArticle
999			_c3426 _d3426